

Claims 1-10 were originally pending in the application. Claims 1-9 were withdrawn from further consideration in view of a Restriction Requirement previously submitted by Applicant. Claims 16-21 have been canceled without prejudice. New Claims 22-24 have been added. Applicant submits that these amendments are properly supported in the specification, and that no new matter has been added.

In the Office Action issued June 12, 2001, Claim 10 was rejected under 35 U.S.C. §103 as being unpatentable over U.S. Patent No. 5,650,398 to Krumdieck et al. in view of an article by Stuart et al. Applicant submitted arguments against these rejections in the response mailed December 12, 2001. However, Applicant requests that the arguments be considered in light of the amendments submitted above. Applicant respectfully requests reconsideration of the rejection of the claims in view of the prior arguments, and submits that the claims are now in condition for allowance.

Respectfully submitted,

Date: March 26, 2003

By Monique A. Morneau  
Monique A. Morneau, Reg. No. 37,893  
WALLENSTEIN & WAGNER, LTD.  
311 South Wacker Drive, 53rd Floor  
Chicago, Illinois 60606  
(312) 554-3300

170282

I hereby certify that this paper or fee is being deposited with the United States Postal Service by first-class mail, postage prepaid, in an envelope addressed to: COMMISSIONER FOR PATENTS, Washington, D.C. 20231, ATTN: BOX RESPONSE/NO FEE, on March 26, 2003.

Susan M. Franklin  
Typed Name

Signature

Date

Susan M. Franklin 3.26.03

MARKED-UP CLAIMS

10. (Three Times Amended) A method of treatment of [the human or animal] a mammalian body comprising [the use of] administering a medicament effective on a cC1qR binding domain [or an inhibitor thereof].

11. (Amended) The method of treatment of Claim 10 wherein administering the cC1qR binding domain [is] includes administering a complement ubiquitin (CUB) domain.

12. (Amended) The method of treatment of Claim [11] 10 wherein the treatment includes administering [a medicament] the cC1qR binding domain to be effective on [a] complement ubiquitin (CUB) domain functionality.

13. (Amended) The method of treatment of Claim [12] 10 wherein treatment includes administering [to the mammal] a therapeutically effective quantity of [medicament to effect CUB] a complement ubiquitin (CUB) domain.

14. (Amended) The method of treatment of Claim [12] 10 wherein treatment includes administering to the mammal a therapeutically effective quantity of a [medicament] cC1qR binding domain [to effect CUB functionality] useful in the treatment [of conditions selected from the group of initiation] and maintenance of inflammation[, myocardial infarction, brain ischemia, gut ischemia, rheumatoid arthritis, systemic lupus erythematosus, burns, immune complex and nephritis, the binding of B-amyloid to C1q and opsonisation].

15. (Amended) The method of treatment of Claim 10 wherein the cC1qR binding domain has the sequence selected from the group consisting of SEQ ID NOS 1- 3.

Please cancel claims 16-21.

Please add new claims:

22. The method of treatment of Claim 10 wherein the method further includes using an inhibitor of the cC1qR binding domain.

23. The method of treatment of Claim 10 comprising administering a cC1qR binding domain for binding a ligand to inhibit complement activation.

24. The method of treatment of claim 23 further includes inhibiting complement activation involved in the initiation and maintenance of inflammation.